Hexamethylene bisacetamide inhibits malignant phenotype in T-ALL cell lines.

Cecchinato, V; Erba, E; Basile, A; Scarpati, B; Fazi, C; Brando, B; Comi, P; Chiaramonte, R

Cecchinato, V; Erba, E; Basile, A; Scarpati, B; Fazi, C; Brando, B; Comi, P; Chiaramonte, R.

Affiliation

Cecchinato V; Department of Biomedical Science and Technology, University of Milano, via Fratelli Cervi 93, 20090 Segrate, and Transplant Immunology and Haematology Laboratory, Niguarda-Ca'Granda Hospital, Milano, Italy.

Leuk Res ; 32(5): 791-7, 2008 May.

Article in En | MEDLINE | ID: mdl-17964649

Subject(s)

Acetamides/pharmacology; Antineoplastic Agents/pharmacology; Leukemia-Lymphoma, Adult T-Cell/drug therapy; Cell Line, Tumor; Cyclin-Dependent Kinase 4/analysis; Humans; Leukemia-Lymphoma, Adult T-Cell/pathology; Proto-Oncogene Proteins c-bcl-2/physiology; Receptor, Notch1/physiology; Signal Transduction; Triglycerides/pharmacology; Tumor Suppressor Protein p53/physiology; gamma-Aminobutyric Acid/analogs & derivatives; gamma-Aminobutyric Acid/pharmacology

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Leukemia-Lymphoma, Adult T-Cell / Acetamides / Antineoplastic Agents Limits: Humans Language: En Journal: Leuk Res Year: 2008 Document type: Article Affiliation country: Italy Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links